Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 20 10:59AM ET
14.39
Dollar change
-0.06
Percentage change
-0.42
%
IndexRUT P/E11.82 EPS (ttm)1.22 Insider Own6.33% Shs Outstand57.33M Perf Week1.48%
Market Cap829.87M Forward P/E6.37 EPS next Y2.26 Insider Trans0.05% Shs Float54.02M Perf Month35.50%
Income70.20M PEG- EPS next Q0.46 Inst Own92.48% Short Float4.92% Perf Quarter0.63%
Sales1.13B P/S0.73 EPS this Y-23.91% Inst Trans-2.10% Short Ratio6.16 Perf Half Y-12.26%
Book/sh-13.35 P/B- EPS next Y-0.66% ROA5.83% Short Interest2.66M Perf Year-49.44%
Cash/sh5.31 P/C2.71 EPS next 5Y- ROE- 52W Range9.93 - 28.99 Perf YTD-23.98%
Dividend Est.0.57 (3.97%) P/FCF88.28 EPS past 5Y- ROI8.10% 52W High-50.36% Beta1.07
Dividend TTM0.60 (4.17%) Quick Ratio1.79 Sales past 5Y0.35% Gross Margin65.47% 52W Low44.99% ATR (14)0.72
Dividend Ex-DateMay 28, 2024 Current Ratio2.29 EPS Y/Y TTM-25.47% Oper. Margin20.17% RSI (14)68.03 Volatility4.53% 4.51%
Employees2200 Debt/Eq- Sales Y/Y TTM1.25% Profit Margin6.20% Recom3.75 Target Price15.00
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q105.38% Payout49.22% Rel Volume0.53 Prev Close14.45
Sales Surprise8.50% EPS Surprise67.50% Sales Q/Q3.64% EarningsMay 09 BMO Avg Volume431.53K Price14.39
SMA2022.43% SMA5018.81% SMA200-7.56% Trades Volume60,721 Change-0.42%
Date Action Analyst Rating Change Price Target Change
Oct-20-23Initiated Wolfe Research Peer Perform
Jan-06-23Downgrade Morgan Stanley Equal-Weight → Underweight $28
Sep-08-22Initiated BTIG Research Neutral
Aug-01-22Initiated Morgan Stanley Equal-Weight $33
Jun-21-22Initiated BofA Securities Underperform $25
May-13-24 11:52AM
May-10-24 02:12PM
May-09-24 10:54AM
06:30AM
06:00AM
05:00PM Loading…
May-01-24 05:00PM
Apr-23-24 05:00PM
Mar-06-24 06:00AM
Feb-10-24 08:55AM
Feb-09-24 10:07PM
11:43AM
07:45AM
07:07AM
06:30AM
06:00AM
05:00PM Loading…
Feb-07-24 05:00PM
Jan-24-24 05:00PM
Jan-21-24 08:33AM
Jan-09-24 06:00AM
Dec-14-23 05:00PM
Dec-01-23 06:00AM
05:13AM
Nov-29-23 05:00PM
Nov-22-23 09:34AM
Nov-21-23 07:23AM
07:15AM
07:13AM
05:30AM
05:00AM
Nov-14-23 10:00AM
06:50AM Loading…
Oct-31-23 06:50AM
Oct-25-23 05:00PM
Sep-28-23 08:10PM
Sep-06-23 05:00PM
Aug-11-23 06:08AM
Aug-08-23 10:19PM
06:30AM
06:00AM
Jul-11-23 05:00PM
Jun-30-23 06:15AM
Jun-21-23 08:00PM
May-20-23 08:26AM
May-15-23 05:38PM
05:00PM
09:30AM
09:30AM
May-13-23 08:16AM
12:05AM
May-12-23 06:30AM
06:15AM
06:00AM
May-01-23 01:08PM
Apr-26-23 08:00PM
Apr-22-23 07:20AM
Apr-21-23 06:15PM
Apr-20-23 05:00PM
Mar-26-23 08:45AM
Mar-22-23 06:46AM
Mar-10-23 10:32AM
Feb-24-23 10:00AM
05:50AM
Feb-22-23 05:00PM
Feb-16-23 07:28AM
Feb-15-23 04:53PM
05:32AM
Feb-14-23 06:54PM
12:08PM
06:30AM
06:00AM
Feb-08-23 05:00PM
Jan-30-23 01:25PM
Jan-25-23 07:00AM
Jan-24-23 05:00PM
Jan-21-23 06:16PM
Dec-20-22 11:34AM
10:29AM
06:30AM
06:00AM
Dec-14-22 05:00PM
Nov-08-22 10:03AM
Nov-07-22 06:50AM
Nov-03-22 05:00PM
Nov-01-22 06:50AM
Sep-16-22 04:30PM
Sep-14-22 06:00AM
Aug-18-22 05:00PM
Aug-15-22 06:30AM
06:00AM
Aug-05-22 09:01AM
Jul-05-22 05:00PM
Jun-29-22 12:06PM
May-13-22 06:30AM
May-09-22 04:05PM
Apr-19-22 06:50AM
Embecta Corp. engages in the provision of medical devices used in the treatment of diabetes. Its products include pen needles, syringes, and safety devices complemented by a digital application. The company was founded in 1924 and is headquartered in Parsippany, NJ.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Melcher David FDirectorFeb 12 '24Buy16.252,00032,50045,080Feb 12 07:08 PM
Melcher David FDirectorSep 08 '23Buy15.776,23398,27127,698Sep 08 09:47 PM
Kurdikar DevdattPresident and CEOAug 10 '23Buy21.815,000109,050244,791Aug 10 05:11 PM
Mann Jeffrey ZSVP, GC, Head Corp. Dev., SecyAug 10 '23Buy21.674,700101,84955,333Aug 10 05:10 PM
Elguicze JacobSVP and CFOAug 10 '23Buy21.664,625100,19566,027Aug 10 05:09 PM